Ikena Oncology Net Worth
Ikena Oncology Net Worth Breakdown | IKNA |
Ikena Oncology Net Worth Analysis
Ikena Oncology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ikena Oncology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ikena Oncology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ikena Oncology's net worth analysis. One common approach is to calculate Ikena Oncology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ikena Oncology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ikena Oncology's net worth. This approach calculates the present value of Ikena Oncology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ikena Oncology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ikena Oncology's net worth. This involves comparing Ikena Oncology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ikena Oncology's net worth relative to its peers.
Enterprise Value |
|
To determine if Ikena Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ikena Oncology's net worth research are outlined below:
| Ikena Oncology generated a negative expected return over the last 90 days | |
| Ikena Oncology may become a speculative penny stock | |
| Ikena Oncology has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9.16 M. Net Loss for the year was (68.17 M) with loss before overhead, payroll, taxes, and interest of (48.7 M). | |
| Ikena Oncology currently holds about 192.81 M in cash with (79.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ikena Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Dukes Iain D. of 23419 shares of Ikena Oncology at 14.92 subject to Rule 16b-3 |
Ikena Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ikena Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ikena Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Ikena Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ikena Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ikena Oncology backward and forwards among themselves. Ikena Oncology's institutional investor refers to the entity that pools money to purchase Ikena Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sofinnova Ventures | 2024-06-30 | 382.6 K | Blackrock Inc | 2024-06-30 | 354.8 K | Millennium Management Llc | 2024-06-30 | 354.7 K | Goldman Sachs Group Inc | 2024-06-30 | 273.8 K | Geode Capital Management, Llc | 2024-09-30 | 271 K | Barclays Plc | 2024-06-30 | 196 K | Two Sigma Advisers, Llc | 2024-06-30 | 173.2 K | Citadel Advisors Llc | 2024-09-30 | 165 K | Bridgeway Capital Management, Llc | 2024-09-30 | 158.4 K | Bvf Inc | 2024-09-30 | 4.8 M | Blue Owl Capital Holdings Lp | 2024-09-30 | 4.1 M |
Follow Ikena Oncology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 82.52 M.Market Cap |
|
Project Ikena Oncology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.42) | (0.45) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.40) | (0.38) |
When accessing Ikena Oncology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ikena Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ikena Oncology's profitability and make more informed investment decisions.
Please note, the presentation of Ikena Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ikena Oncology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ikena Oncology's management manipulating its earnings.
Evaluate Ikena Oncology's management efficiency
Ikena Oncology has return on total asset (ROA) of (0.2206) % which means that it has lost $0.2206 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3709) %, meaning that it created substantial loss on money invested by shareholders. Ikena Oncology's management efficiency ratios could be used to measure how well Ikena Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Ikena Oncology's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.7 M, whereas Other Current Assets are forecasted to decline to about 2.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.07 | 4.27 | |
| Tangible Book Value Per Share | 4.07 | 4.27 | |
| Enterprise Value Over EBITDA | 0.36 | 0.38 | |
| Price Book Value Ratio | 0.48 | 0.51 | |
| Enterprise Value Multiple | 0.36 | 0.38 | |
| Price Fair Value | 0.48 | 0.51 | |
| Enterprise Value | -26.9 M | -25.6 M |
Leadership effectiveness at Ikena Oncology is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 0.9337 | Revenue 659 K | Quarterly Revenue Growth (0.88) | Revenue Per Share 0.014 | Return On Equity (0.37) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ikena Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ikena Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ikena Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ikena Oncology time-series forecasting models is one of many Ikena Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ikena Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ikena Oncology Earnings per Share Projection vs Actual
Ikena Oncology Corporate Management
| Navin MS | VP Quality | Profile | |
| Sabine Ruppel | VP Discovery | Profile | |
| Jennifer Schroeder | Sr Operations | Profile | |
| Rebecca Cohen | Corporate Relations | Profile | |
| Valdas Jurkauskas | Senior Operations | Profile | |
| MBA MD | Chief Officer | Profile | |
| David MS | Senior Operations | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Revenue Per Share 0.014 | Quarterly Revenue Growth (0.88) | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.